NCT00035243

EPO906 Therapy in Patients With Advanced Kidney Cancer

An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Renal Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.

Conditions

• Kidney Neoplasms

Interventions

Type	Name	Description
DRUG	epothilone b	EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.

Timeline

• Start date: 2002-04-01
• Primary completion: 2003-08-01
• First posted: 2002-05-03
• Last updated: 2012-04-17

Locations

8 sites across 2 countries: United States, France